AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Pancreatic Adenocarcinoma - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if an experimental drug called AVB-S6-500 is a safe and effective treatment for your cancer when given with nab-paclitaxel and gemcitabine.

What is the Condition Being Studied?

Pancreatic Adenocarcinoma

Who Can Participate in the Study?

Adults with pancreatic cancer who:
- Have recurrent, locally advanced, or metastatic cancer
- Have not received any prior treatment for this cancer

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- One group will take the study drug, AVB-S6-500, in combination with nab-paclitaxel and gemcitabine
-- The other group will only take nab-paclitaxel and gemcitabine
- Have blood draws
- Give urine samples
- Have regular CT or MRI scans

Study Details

Full Title
A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00108583
NCT: NCT04983407
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698